Mandate

Vinge advises Doro in connection with the acquisition of IVS

May 15, 2013

Vinge has advised Doro in connection with the acquisition of the German distributor IVS Industrievertretung Schweiger GmbH (“IVS”). The acquisition price for IVS, including the maximum additional purchase price in 2014 and 2015, amounts to EUR 17.6 million on a cash and debt free basis. The acquisition is financed through a combination of existing cash and bank loans and Doro also has an option to finance part of the acquisition with Doro shares.

Doro’s products and solutions are available in more than 30 countries spanning five continents and the product range includes mobile phones, apps and software, fixed telephony, telecare and solutions within mHealth. Doro’s turnover in 2012 was SEK 837.5 million and the company’s shares are listed on OMX Nasdaq Stockholm, Nordic List, Small-cap.

Vinge primarily advised Doro on the capital markets and corporate law issues pertaining to the acquisition. Vinge’s team consisted of responsible partner Johan Winnerblad together with associates Charlotte Levin, Matthias Pannier, Dain Nevonen and Christian Hybbinette. 

Related

Vinge advised Precise Biometrics

Vinge has advised Precise Biometrics AB in connection with the merger with Fingerprint Cards.
March 27, 2026

Vinge has advised Xspray Pharma in connection with its rights issue

Vinge has advised Xspray Pharma AB (publ) in connection with a rights issue of approximately SEK 83 million before transaction costs, with an over-allotment issue of approximately SEK 30 million.
March 26, 2026

Vinge advises Diamyd Medical in connection with directed issuances of shares and warrants of up to SEK 1,166 million

Vinge advises Diamyd Medical Aktiebolag (“Diamyd Medical”), listed on Nasdaq First North Growth Market, in connection with directed issuances of shares and warrants whereby Diamyd Medical receives gross proceeds of approximately SEK 1,166 million, if all warrants are exercised.
March 25, 2026